Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (241-250 of 336) with videos related to

Pageof 34
Sort By:
Frontiers in Bioscience (Elite Edition)|September 24, 2023
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic ScoreGiulia Mazzaschi, Alessandro Lazzarin, Matteo Santoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trialAndrea Ardizzoni, Marcello Tiseo, Luca Boni, et al.
European Urology Oncology|April 4, 2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 StudyFrancesco Massari, Veronica Mollica, Ondrej Fiala, et al.
Clinical Genitourinary Cancer|April 14, 2024
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry StudyVeronica Mollica, Francesco Massari, Marco Maruzzo, et al.
Immunotherapy|May 16, 2023
Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumabSatoru Taguchi, Taketo Kawai, Sebastiano Buti, et al.
Cancers|May 16, 2023
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 StudySara Elena Rebuzzi, Matteo Brunelli, Francesca Galuppini, et al.
JCO Global Oncology|July 8, 2025
Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 StudyMimma Rizzo, Andrey Soares, Shilpa Gupta, et al.
Cancers|October 28, 2023
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and SurvivalKhalil Choucair, Caroline Nebhan, Alessio Cortellini, et al.
Clinical Genitourinary Cancer|August 1, 2020
Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective StudyMaria Giuseppa Vitale, Stefania Pipitone, Marta Venturelli, et al.
Clinical & Experimental Metastasis|February 16, 2024
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinationsMichele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, et al.
Pageof 34

Showing results (241-250 of 336) with videos related to

Sort By:
Pageof 34
Frontiers in Bioscience (Elite Edition)|September 24, 2023
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic ScoreGiulia Mazzaschi, Alessandro Lazzarin, Matteo Santoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trialAndrea Ardizzoni, Marcello Tiseo, Luca Boni, et al.
European Urology Oncology|April 4, 2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 StudyFrancesco Massari, Veronica Mollica, Ondrej Fiala, et al.
Clinical Genitourinary Cancer|April 14, 2024
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry StudyVeronica Mollica, Francesco Massari, Marco Maruzzo, et al.
Immunotherapy|May 16, 2023
Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumabSatoru Taguchi, Taketo Kawai, Sebastiano Buti, et al.
Cancers|May 16, 2023
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 StudySara Elena Rebuzzi, Matteo Brunelli, Francesca Galuppini, et al.
JCO Global Oncology|July 8, 2025
Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 StudyMimma Rizzo, Andrey Soares, Shilpa Gupta, et al.
Cancers|October 28, 2023
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and SurvivalKhalil Choucair, Caroline Nebhan, Alessio Cortellini, et al.
Clinical Genitourinary Cancer|August 1, 2020
Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective StudyMaria Giuseppa Vitale, Stefania Pipitone, Marta Venturelli, et al.
Clinical & Experimental Metastasis|February 16, 2024
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinationsMichele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, et al.
Pageof 34